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1 Introduction
Molecular components of the extracellular matrix (ECM) are critical for matrix stabilization, cellular 
differentiation, and tissue morphogenesis. Once thought to function only as the extracellular glue that 
primarily binds cells together, proteoglycans in the ECM carry out a diverse array of activities and can 
be grouped into five functionally based families: (i) hyalectins (lecticans), which contain lectin-like car-
bohydrate-recognition domains (CRDs) and bind hyaluronan (HA); (ii) heparan sulfate (HS) proteo-
glycans that sequester growth factors via their HS chains; (iii) small leucine-rich proteoglycans (SLRPs) 
containing leucine-rich domains that interact with collagens and other ECM proteins; (iv) phosphacans 
that function primarily as receptor-like protein-tyrosine phosphatases; and (v) part-time proteoglycans 
that reside both on the cell surface and in the ECM. More than 40 cDNAs encoding proteoglycan core 
proteins have been discovered thus far [1]. For the sake of brevity, this chapter will focus only on the 
four lecticans that bind HA (Figure 1): Aggrecan, neurocan, brevican, and versican. 
All lecticans have two N-terminal Link domains, one immunoglobulin-like module, a central gly-
cosaminoglycan (GAG)-attachment region, and one or more EGF-like domains in the C-terminus. 
The lecticans are post-translationally modified by O-Linked GAG chains on Ser residues of multiple 
Ser-Gly dipeptide repeats. Aggrecan, versican, neurocan, and brevican contain 120, 20, 7, and 3 po-
tential sites, respectively. Generally, the CS chains of the lecticans maintain structural integrity of the 
tissue ECM by serving as barrier functions to limit the growth and migration of cells. For example, 
the CS chains of neurocan and brevican act as barriers to inhibit neurite outgrowth and migration so 
that, hypothetically, dendrites are available for longer periods of time in their local environment to 
make the correct synaptic junctions [2] and set up guidance cues for migration [3,4]. The barrier func-
tions of the lecticans exist on two levels: (i) as mechanical barriers, the proteoglycans form neuronal 
nets to physically constrain neurite outgrowth [5] and (ii) as cell signaling barriers, the proteoglycans 
can activate intracellular signaling pathways regulated by the Rho-family GTPases to promote the 
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disruption of the actin cytoskeleton and growth cone collapse [6]. In addition to the barrier functions, 
GAGs in close proximity may also serve to sequester water to maintain tissue hydration. 
 Neurocan and brevican are primarily neural ECM lecticans, whereas aggrecan is found mainly in 
cartilage and versican is in vascular vessel walls. Aggrecan and versican play minor, albeit important 
and sometimes transient, functions in central nervous system (CNS) development and ECM composi-
tion [7]. Aggrecan, versican, and brevican are proteolytically degraded by ADAMTS-1/4 (a disintegrin 
and metalloproteinase with thrombospondin motifs) metalloproteases, whereas neurocan is processed 
by matrix metalloproteinases 2 (MMP-2). Metalloprotease cleavage of the lecticans is part of their nor-
mal turnover process and an increase in metalloprotease activity in tissues such as the brain may be 
a prerequisite for diseases such as Alzheimer’s disease and epilepsy [8]. Numerous reviews have de-
scribed the biology, chemistry, and physiological impact of these lecticans, their splice variants, and 
their cohorts of interacting partners on matrix and cellular composition in tissues [9-19]. 
2 Aggrecan 
Chondrocytes synthesize and secrete the ECM components of cartilage. The most abundant pro-
tein is collagen II, which is up to 60% of the dry weight of the cartilage, followed by aggrecan (35% of 
dry weight). All other components make up the remaining 5% of the tissue dry weight [20]. The ag-
grecan core protein is heavily modified in the endoplasmic reticulum (ER)/Golgi by addition of chon-
droitin sulfate (CS) and keratan sulfate (KS) chains prior to secretion from the cell. These glycosami-
noglycan (GAG) modifications greatly increase the molecular mass of the molecule by at least four- to 
five-fold over the core protein alone. After aggrecan is secreted from chondrocytes, it interacts with 
HA and Link proteins to form organized structures—proteoglycan aggregates. The CS and KS chains 
Figure 1. Lectican domain organization. The common domains of the lecticans include two globular domains, G1 and 
G3, and a CS/KS-attachment region (red). The G1 region contains two Link modules (blue) that bind to HA. The G3 
domain contains at least two EGF-like regions (yellow), a carbohydrate recognition domain (CRD; green), and a short 
complement regulatory region (SRC; black). Glycanated aggrecan is the largest of the lecticans, containing up to 120 CS 
and KS chains, in addition to an Ig-fold sequence (IGD; brown) and a G2 region (orange). The four splice variants of 
versican (V0–V3) contain N- and C-terminal regions that are very homologous with aggrecan and differing CS-attach-
ment regions (except for V3) encoded by different exons, which are preferentially spliced depending on the host cell-
type. Versican V0 contains the longest core protein of all the lecticans and contains up to 20 CS chains. Neurocan, with 
seven CS chains, and brevican, with three CS chains, differ in size and glycanation and do not contain an Ig-domain 
(IGD). Metalloproteolyic cleavage sites for ADAMTS-1/4 or MMP-2 (in neurocan only) are represented by the arrows. 
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are highly sulfated, giving the entire aggrecan molecule a high polyanionic charge, which attracts and 
binds large amounts of water and cations. Seventy percent of the wet weight of cartilage is due to water 
sequestered by the high-density negative charge associated with the sulfate and carboxylate groups on 
the GAGs, giving the tissue a gel-like quality [21]. The viscoelastic behavior of the GAGs in aggrecan-
HA aggregates is directly responsible for the unique physical properties of articular cartilage, which in-
cludes compressive resilience during joint loading and load distribution over the surface of the tissue. 
The aggrecan core protein consists of three disulfide-bonded globular domains, G1, G2, and G3, 
and a GAG-attachment region, primarily containing CS (Figure 1). The N-terminus of the G1 domain 
contains the HA-binding regions, which consist of two Link domains of ~93 amino acids with homol-
ogy to the Link domains found in other hyalectins such as the hyaluronic acid receptor for endocytosis 
(HARE), TSG-6, CD44, and lymphatic vascular endothelial hyaluronan receptor 1 (LYVE-1) (Harris & 
Weigel in Vasta & Ahmed, Animal Lectins [2009], Chapter 12). Another ECM protein called “Link pro-
tein” (due to its function of “linking” aggrecan and HA) binds to both HA, with its own Link domain, 
and the G1 domain of aggrecan via an Ig-fold [22]. This trimeric (HA-Link protein-aggrecan) complex 
creates a stable and long-lasting three-dimensional structure that is strong, yet flexible enough to with-
stand the high-impact physical forces constantly experienced by our joints and tissues. Binding studies 
using surface plasmon resonance show that a fragment of aggrecan comprising G1 and G2 binds HA 
with a Kd of 226 nM, whereas the Link protein binds HA with a Kd of 89 nM, a higher affinity [23]. 
The G2 domain shares some structural features with G1, but lacks the ability to bind HA. It is 
heavily substituted with KS chains and N-terminally adjacent to the CS attachment region. Both G1 
and G2 domains inhibit aggrecan monomer secretion until the protein is fully modified and correctly 
folded. On the other hand, the G3 domain is known to promote secretion of the monomer and pro-
gression of the protein along the secretory pathway after GAG addition [24]. The region between the 
G1 and G2 domains, the interglobular domain (IGD region), is cleaved by proteolysis during normal 
aggrecan turnover. Conditions in which there is an increased exposure to, or expression of, inflam-
matory cytokines (e.g., as found in arthritis) promote the degeneration of aggrecan and weakening of 
the cartilage. The loss of the G2 through G3 portion of aggrecan changes the physicochemical attri-
butes of the HA-aggrecan aggregate structure, which is difficult to repair, since the G1 domain frag-
ment may remain bound to HA and thus prevent the binding of newly synthesized intact aggrecan 
monomers with HA [25–27]. 
The G3 or C-terminal domain of aggrecan contains two EGF-like domains (EGF1 and EGF2), a 
CRD, and a complement regulatory protein B component or short complement repeat (SCR). The 
primary role of the G3 domain is to aid secretion of the aggrecan monomer from chondrocytes after 
protein synthesis and GAG assembly in the ER/Golgi. The G3 domain is essentially a cap that pre-
vents degradation, while the individual subdomains within G3 assist with processing, trafficking, 
and secretion of the heavily glycosylated core protein [28, 29]. The G3 domain in articular cartilage is 
primarily associated with newly synthesized or immature aggrecan, whereas most mature aggrecan 
core proteins have lost their G3 domains in age-related processes [30]. 
Assembly of the aggrecan supramolecular structure is a highly ordered process that begins on 
the chondrocyte surface. In humans, HA is made at the cell surface by any of the three membrane-
bound HA synthase isozymes (HAS1, 2, or 3) [31–33]. As HA is extruded from the cell surface, newly 
synthesized aggrecan and Link proteins may bind with the HA to form aggregates. The Link pro-
tein is required for proper alignment and ordering of the aggrecan along the HA [34]. The details for 
how Link protein is secreted and helps assemble these structures are not known. Furthermore, since 
cartilage is an acellular tissue, special processes are needed to facilitate the assembly of new ECM 
components many cell diameters away from the site of synthesis. One facilitation mechanism is that 
not all immature aggrecan monomers can bind HA, which is advantageous for development, since 
these aggrecan monomers then have time to travel away from the cell (i.e., the site of synthesis) be-
fore they become anchored to a HA molecule. This delayed incorporation of aggrecan may be the re-
sult of structural changes in the G1 domain [35, 36], or the interaction of the G3 domain with other 
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ECM structural proteins such as fibulin 1/2, tenacin-C and tenacin-R [37]. Unincorporated aggrecan 
has a short half-life, 24 h or less, whereas aggrecan incorporated into HA aggregates has a half-life of 
many years [38]. The immature unassociated aggrecan monomer needs to undergo several physical 
changes, depending on the environment, or it will be degraded. Once aggrecan binds with HA and 
Link protein, the molecule is very stable and can proceed to assemble into supramolecular aggre-
gates with other aggrecan and ECM molecules such as biglycan, decorin, fibulin, and the collagens. 
3 Versican 
Human versican is a “versatile” molecule found in the ECM of connective tissues and the ECMs 
of a wide variety of “soft” tissues, including brain, arterial and venous vasculature, epithelia, and 
mesenchyme. The full-length core protein is the longest of the four lecticans, discussed in this chap-
ter, and is encoded by a gene that extends over 100 kb and includes 15 exons. The core protein is or-
ganized in a fashion similar to the other lecticans (Figure 1) with a HA-binding globular G1 domain 
at the N-terminus and two GAG attachment domains, termed GAG- and GAG-β, in the middle re-
gion encoded by 3 and 5.3 kb exons, respectively. The C-terminal portion of the protein contains two 
EGF-like domains, a CRD and a complement regulatory region. Alternative splicing of versican re-
sults in three variants (termed V1, V2, and V3), as well as full-length (V0), that are encoded by 3, 9, 
6.5, and 12 kb transcripts, respectively. The molecular masses for these variants (V0–V3) are 370, 262, 
180, and 72 kDa. V1 does not include GAG-, V2 does not contain GAG-β, andV3 lacks both GAG at-
tachment regions and is, therefore, technically not a proteoglycan [19]. 
Versican is the major proteoglycan in most arteries and veins, where it interacts with HA and 
Link proteins to form stable high molecular mass aggregates that fill spaces not occupied by other 
proteins such as collagen and elastin. The interaction of versican with other proteins and HA provide 
the blood vessels with walls that are both firm and elastic, thus able to contract or dilate in response 
to blood pressure, temperature changes, etc. In addition to normal turnover, inflammation and aging 
promote the degradation of versican, a process in which the core protein is cleaved by members of 
the ADAMS-TS metalloproteases family, in addition to matrilysin and plasmin. The loss of versican 
in the blood vessel walls may contribute to a weakening of the overall structure, giving rise to aneu-
rysms and pseudoaneurysms [39, 40]. 
Arterial smooth muscle cells (ASMC) are the primary source of versican in both arteries and blood 
vessels and express the transcripts to produce V0, V1, and V3 [41, 42]. Platelet-derived growth factor, 
through the MAP kinase pathway, stimulates an increase in versican core protein transcription and 
CS chain elongation [43]. Conversely, IL-1β produced by inflammatory-stimulated macrophages de-
creases versican expression, suggesting that macrophage binding to vasculature lesions may contrib-
ute to the versican breakdown associated with this pathology [44]. Versican enriched with CS-6 and 
CS-4 chains is involved in the advanced stages of atherosclerotic lesions. Versican is prominent near 
the edges of necrotic cores and in close proximity to lipoproteins [45]. In vitro binding studies dem-
onstrate that multiple low-density lipoprotein (LDL) particles can bind to single CS chains with an 
affinity of 23 nM, and an increase in chain length directly correlates with increased binding of LDL 
particles with the same affinity [18, 46]. Treatment of ASMCs with growth factors such as EGF and 
TGF-β also causes elongation of CS chains on versican and may serve as a positive feedback stimulus 
in the early stages of atherogenesis [47, 48]. 
The increased expression of versican V2, a product of oligodendrocytes, occurs in the periphery of 
brain lesions. In vitro cultures of oligodendrocytes indicate that the expressed versican acts as a linker 
between HA and tenascin-R, forming a rudimentary ECM. Axon regeneration failure is induced due 
to this injury response, since versican mediates growth-cone collapse and growth inhibition through 
its CS chains and core protein sequence [49]. Since all of the lecticans, including versican, present in 
the brain are growth-inhibitory, several methods to eliminate versican have been devised in order to 
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promote axon regeneration. These include the use of antiversican antibodies to eliminate versican ex-
pressing cells via complement-killing in the rat [50] and the infusion of antimitotic agents to prevent 
oligodendrocyte recruitment to the lesion [51]. 
4 Neurocan 
The rat brain proteoglycan, neurocan, was identified and characterized using monoclonal anti-
bodies [52]. During embryonic development, neurocan is commonly found as a 250 kDa monomer, 
and then later during maturation, it occurs as two protein isoforms of 130 and 150 kDa due to prote-
olysis at a MMP-2 cleavage site [53]. The N-terminal 130 kDa segment is the major HA-binding com-
ponent and contains two CS chains, while the C-terminal 150 kDa segment binds with other ECM 
proteins and calcium ions [54]. Expression of neurocan is confined to the CNS, although it is pres-
ent in the developing sensory nerves of the optical and olfactory systems in lower animals [55, 56]. In 
mature brain, the expression of neurocan is very low, but is markedly increased in areas undergoing 
matrix remodeling. In fact, expression of neurocan may be required for remodeling of hippocampal 
synaptic connections during learning and memory-induced changes in synaptic transmissions [57]. 
Neurocan interacts with other molecules via the core protein, its GAG chains, or both. Interact-
ing partners of neurocan can be classified into three different groups. First, the matrix proteins tenas-
cin-C and tenascin-R are important for ECM aggregation during brain development when neurocan 
and heparin, which enhances the activity, are localized to perineuronal nets (PNNs) [58, 59]. Sec-
ond, growth factors associated with mobility such as FGF-2 [60], HB-GAM, and amphoterin [61] in-
teract with neurocan and also bind heparin. Binding with amphoterin and HB-GAM is CS-chain de-
pendent in contrast to FGF-2, which binds to the core protein. These growth factors support neurite 
outgrowth and extension in the developing brain, whereas neurocan serves as a modulator for these 
growth factors. Third, neural cell adhesion molecules such as N-CAM, L1/Ng-CAM, and TAG-1/ax-
onin-1 are involved with neurite outgrowth and navigation. Binding of these cell adhesion molecules 
is CS-dependent, although there is weak binding to the C-terminal portion of the core protein. 
Although neurocan interacts with a wide variety of adhesion, growth, and matrix molecules, the 
neurocan knockout mouse does not exhibit any gross anatomical brain pathologies [62]. Despite the 
involvement of neurocan in modeling of the CNS matrix, the proteoglycan is not required for the fi-
nal outcome of how the brain structure develops. Thus far, the phenotypes of neurocan deficiency 
have only been observed in mice and give no indication of the possible affects on higher-brain func-
tions such as thought and reasoning. Interestingly, an L1/Ng-CAM deficiency causes mental retar-
dation in humans, but causes no physical or mental manifestation in mice, proving that not all ani-
mal models reflect the human condition [63]. 
5 Brevican 
Expression of brevican or brain-enriched hyaluronan-binding protein (BEHAB) is restricted to the 
brain and is particularly enriched in neuroglial sheaths of velate protoplasmic astrocytes in the cere-
bellar granular layer [64] and in PNNs of large neurons [65]. In the rat, brevican is expressed at high 
levels in the neuroaxis of the ventricular zones and may be important for the development of glial 
cells. Brevican was first discovered in rats and cats as a partial protein with a molecular mass of ~38 
kDa [66]. The full-length 160 kDa core protein is now known to be proteolytically cleaved, resulting 
in two physiologically relevant fragments of 100 and 60 kDa [67]. 
The ECM of the brain contains cross-linking proteins called the tenascins, which serve not only as 
part of the lattice that supports the neuronal network of the brain, but also as coregulators of mor-
phogenesis and remodeling associated with injury, learning, and growth. Neurocan binds strongly 
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with tenascin-C, and both proteins increase in expression during tissue regeneration [68]. On the 
other hand, brevican binds with tenascin-R via its fibronectin III domain in a CS-independent man-
ner [69]. Tenascin-R, HA, and the lecticans, especially brevican and neurocan, are basic components 
of the PNNs first described by Camillo Golgi and Santiago Ramon y Cajal in the 1890s. Neurons and 
glial cells secrete the materials that compose the PNN, which is a reticular net-like feature covering 
these cells that forms the organized lattice material in the intercellular spaces [65]. The PNN, which is 
structurally similar in some ways to the aggrecan-HA proteoglycan aggregates of cartilage, provides 
a tougher shield to protect the enclosed neurons and glial cells from movement within an otherwise 
vulnerable soft tissue matrix. 
Brevican is a unique marker for glioma, a type of cancer that originates within the glial cells of 
the brain and metastasizes very extensively within the cranial ECM, but does not extend outside 
the CNS boundaries [70]. One of the main features of a high-grade glioma is the presence of an un-
derglycosylated form of brevican (B/bΔg), which migrates at 150 kDa on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Other forms of brevican are also present, such as 
a differentially glycosylated form that migrates slightly larger than 160 kDa and the proteolytic by-
products of ADAMTS-4-induced cleavage of the native protein [71–73]. These features are not pres-
ent in other neuropathologies such as Alzheimer’s disease, nonglial tumors, or Parkinson’s disease. 
Like the other lecticans, brevican exerts its inhibitory control on neurite outgrowth and cell migra-
tion via it CS chains. Brevican (B/bΔg), a likely agent for glioma aggressiveness, may tip the balance 
in the favor of growth and migration of neurons. 
6 Conclusion and Future Directions 
Once thought to be ECM components that only hold tissues and organs in place, the lecticans are 
increasing recognized as dynamic molecules that influence cell behaviors through effector protein/
GAG interactions and signaling pathways. The underlying causes of many intrinsic human diseases, 
such as Alzheimer’s disease and stenosis, can be traced to a “malfunction” of one or more lecticans. 
The binding partners and matrix associations of this class of molecules are fairly well understood. 
More exciting future directions will focus on gene regulation and the development of transgenic 
mice with reporter genes inserted within the promoter regions of versican, brevican, and neurocan. 
Since little is known about the cis or trans regulatory elements of how these genes are turned on or 
off, the expression of reporter genes in conjunction with lectican expression will provide answers to 
questions such as how protein expression corresponds with injury or disease and what regulates that 
expression. Since the versican knockout is lethal in mice, reporter genes in this model and others will 
aid our understanding of gene expression during development, disease, and injury and may ulti-
mately provide targets for gene therapeutic interventions. 
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